Kura/Kyowa Kirin’s Ziftomenib Scores In NPM1m AML, But Differentiation Is Key

The company plans to file for accelerated approval with the US FDA next quarter, but there are concerns about how differentiated ziftomenib would be from Syndax’s first in class menin inhibitor.